Venetoclax, a BCL-2 inhibitor, has been tested for use in CML in the preclinical setting and has demonstrated increased apoptosis [128, 129]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.